Hamid Javidi, MD in Aquebogue, NY - Obstetrics & Gynecology

Hamid Javidi, MD is a Obstetrics & Gynecology physician based in Aquebogue, New York. Hamid Javidi is licensed to practice in New York (license number 136191) and his current practice location is 11 Whites Lane, Aquebogue, New York. He can be reached at his office (for appointments etc.) via phone at (631) 722-5506.

NPI number for Hamid Javidi is 1679096317 and his current mailing address is 11 Whites Lane, Aquebogue, New York. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1679096317.

Contact Information

	Hamid Javidi, MD
	11 Whites Lane, Aquebogue, NY 11931
	(631) 722-5506
	Not Available

Physician's Profile

Full Name	Hamid Javidi
Gender	Male
Speciality	Obstetrics & Gynecology
Location	11 Whites Lane, Aquebogue, New York
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1679096317
Provider Enumeration Date: 07/25/2017
Last Update Date: 07/21/2022

Medical Identifiers

Medical identifiers for Hamid Javidi such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1679096317	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207V00000X	Obstetrics & Gynecology	136191 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Hamid Javidi is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Hamid Javidi, MD 11 Whites Lane, Aquebogue, NY 11931 Ph: (631) 722-5506	Hamid Javidi, MD 11 Whites Lane, Aquebogue, NY 11931 Ph: (631) 722-5506

News Archive

New analysis examines pharmacy expenditures for publicly insured children with serious chronic illness

In an analysis of expenditures for outpatient pharmacy products used by publicly insured children with serious chronic illness in California, treating hemophilia accounted for about 40 percent of expenditures but included just 0.4 percent of the group studied, suggesting a need to improve pricing for this and other effective yet high-cost medications, according to a study in the July 28 issue of JAMA.

FDA - all antidepressants need new warning labels

The Food and Drug Administration (FDA) in the United States wants the manufacturers of antidepressant medications to change the labels on their products.

Patient recommendations for rheumatoid arthritis treatment: an interview with Dr Nowell

The study, "When patients write the guidelines: Patient panel recommendations for the treatment of RA," published in Arthritis Research & Care, demonstrated the feasibility of developing CPG recommendations based on a voting panel composed entirely of patients.

Thrombolytic treatment after stroke associated with reduced in-hospital mortality

In a study that included nearly 60,000 patients with acute ischemic stroke, thrombolytic treatment (to help dissolve a blood clot) that was started more rapidly after symptom onset was associated with reduced in-hospital mortality and intracranial hemorrhage and higher rates of independent walking ability at discharge and discharge to home, according to a study in the June 19 issue of JAMA.

Brazilian scientists examine how benzopyrene can cause cancer

Benzo[a]pyrene is a potent carcinogen and mutagen present in cigarette smoke, automotive exhaust, burnt wood fumes, barbecued and smoked meat etc.

Hamid Javidi, MD - Obstetrics & Gynecology in Aquebogue, NY